Bronchitis - Pipeline Insight, 2024

Bronchitis - Pipeline Insight, 2024

DelveInsight’s, “Bronchitis– Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bronchitis Understanding

Bronchitis: Overview

Bronchitis is a condition in which the airways in the lungs, called bronchial tubes, become inflamed and cause coughing, often with mucus. Bronchitis can be acute or chronic.

Symptoms

Signs and symptoms of both acute and chronic bronchitis include:

• a persistent cough, which may produce mucus
• wheezing
• a low fever and chills
• a feeling of tightness in the chest
• a sore throat
• body aches
• breathlessness
• headaches
• a blocked nose and sinuses

Diagnosis

During the first few days of illness, it can be difficult to distinguish the signs and symptoms of bronchitis from those of a common cold.

• Chest X-ray. A chest X-ray can help determine if the patient have pneumonia or another condition that may explain your cough.
• Sputum tests. Sputum can also be tested for signs of allergies.
• Pulmonary function test.

Treatment

Treatment of acute bronchitis is typically divided into two categories: antibiotic therapy and symptom management. Physicians appear to deviate from evidence-based medical practice in the treatment of bronchitis more than in the diagnosis of the condition.

Bronchitis Emerging Drugs Chapters

This segment of the Bronchitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bronchitis Emerging Drugs

• DW 1601: Daewon Pharmaceutical

Daewon Pharmaceutical is developing DW 1601 for the treatment of Bronchitis.

Further product details are provided in the report……..

Bronchitis: Therapeutic Assessment

This segment of the report provides insights about the different Bronchitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Bronchitis

There are approx. 15+ key companies which are developing the therapies for Bronchitis. The companies which have their Bronchitis drug candidates in the most advanced stage, i.e. phase III include, Daewon Pharmaceutical.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Bronchitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bronchitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchitis drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Bronchitis R&D. The therapies under development are focused on novel approaches to treat/improve Bronchitis.

Bronchitis Report Insights

• Bronchitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bronchitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bronchitis drugs?
• How many Bronchitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bronchitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bronchitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Zambon SpA
• Yuhan Corporation
• Theravance Biopharma
• Genentech, Inc.
• GlaxoSmithKline
• Novartis
• SolAeroMed Inc.
• Reata Pharmaceuticals, Inc.
• Pulmatrix
• Pharmaxis
• PharmaKing
• NovaBiotics.
• Merck Sharp & Dohme Corp.
• Johnson & Johnson Pharmaceutical Research & Development
• Ionis Pharmaceuticals, Inc.
• Incyte Corporation
• EmeraMed
• Daewon Pharmaceutical Co., Ltd.
• Chong Kun Dang Pharmaceutical
• Breath Therapeutics Inc.
• Boehringer Ingelheim
• BioMarck Pharmaceuticals
• Beyond Air
• AstraZeneca
• APT Pharmaceuticals, Inc.
• Abgenix
• Abbott

Key Products

• N-acetylcysteine (NAC)
• YHD001
• V-306 candidate vaccine
• Tiotropium
• TD-4208
• Pirfenidone
• SB-240563 (Mepolizumab)
• AD 237
• S1226
• Bardoxolone methyl
• PUR003
• TPI 1020
• N02RS1
• Combination of Broussonetia spp and Lonicera spp
• QBW251
• Cysteamine
• MK-0476
• levofloxacin
• ION-827359
• Itacitinib
• GSK573719
• Emeramide
• DW1601
• CKD-497
• Liposomal Cyclosporine A
• BIBW 2948
• BIO-11006
• Nitric Oxide
• Aclidinium bromide
• Formoterol/Budesonide
• ABX-IL8